Anders Himmelmänn

6.4k citations

106 papers · 2.9k indexed · 2 hit papers · h-index 30

Impact in

Internal Medicine top 1%
- Venous Thromboembolism Diagnosis and Management
Cardiology and Cardiovascular Medicine top 1%
- Antiplatelet Therapy and Cardiovascular Diseases
- Acute Myocardial Infarction Research
- Atrial Fibrillation Management and Outcomes
- Blood Pressure and Hypertension Studies

Papers in ⓘ

Internal Medicine 16
- Venous Thromboembolism Diagnosis and Management 16
Cardiology and Cardiovascular Medicine 76
- Antiplatelet Therapy and Cardiovascular Diseases 53
- Acute Myocardial Infarction Research 21
- Blood Pressure and Hypertension Studies 14
- Atrial Fibrillation Management and Outcomes 12

Co-authors: Stefan James (59 shared papers)Lars Wallentin (53 shared papers)Robert F. Storey (50 shared papers)Philippe Gabríel Steg (40 shared papers)Richard C. Becker (33 shared papers)Thomas Hedner (6 shared papers)Steen Husted (20 shared papers)Hugo A. Katus (20 shared papers)
Journals: American Heart Journal (10 papers)European Heart Journal (9 papers)Journal of Hypertension (8 papers)Journal of the American College of Cardiology (7 papers)Blood Pressure (6 papers)
Partner nations: Sweden United States United Kingdom

In The Last Decade

Anders Himmelmänn

105 papers receiving 2.8k citations

Hit Papers

align trajectories log scale

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA 2020 · 304 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 New England Journal of Medicine
2019 New England Journal of Medicine

Peers

Countries citing papers authored by Anders Himmelmänn

Since Specialization

Citations

This map shows the geographic impact of Anders Himmelmänn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anders Himmelmänn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anders Himmelmänn more than expected).

Fields of papers citing papers by Anders Himmelmänn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anders Himmelmänn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anders Himmelmänn. The network helps show where Anders Himmelmänn may publish in the future.

Co-authors

The 25 scholars most cited alongside Anders Himmelmänn, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anders Himmelmänn Line = papers co-authored together Anders Himmelmänn links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 106 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA New England Journal of Medicine ·S. Claiborne Johnston, Pierre Amarenco, Hans Denison, Scott Evans, Anders Himmelmänn, Stefan James, Mikael Knutsson, Per Ladenvall, Carlos A. Molina, Yongjun Wang Hit paper breakdown →	2020	304
2	Ticagrelor in Patients with Stable Coronary Disease and Diabetes New England Journal of Medicine ·Philippe Gabríel Steg, Deepak L. Bhatt, Tabassome Simon, Kim Fox, Shamir R. Mehta, Robert A. Harrington, Claes Held, Marielle Andersson, Anders Himmelmänn, Wilhelm Ridderstråle, Maria Leonsson‐Zachrisson, Yuyin Liu, Grzegorz Opolski, D. A. Zateyshchikov, Junbo Ge, José Carlos Nicolau, Ramón Corbalán, Jan H. Cornel, Petr Widimský, Lawrence A. Leiter Hit paper breakdown →	2019	204
3	Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial European Heart Journal ·Daniel Lindholm, Christoph Varenhorst, Christopher Cannon, Robert A. Harrington, Anders Himmelmänn, Juan Maya, Steen Husted, Philippe Gabríel Steg, Jan H. Cornel, Robert F. Storey, Staci R. Stevens, Lars Wallentin, Stefan James	2014	138
4	Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study European Heart Journal ·Emil Hagström, Stefan James, Maria Bertilsson, Richard C. Becker, Anders Himmelmänn, Steen Husted, Hugo A. Katus, Philippe Gabríel Steg, Robert F. Storey, Agneta Siegbahn, Lars Wallentin	2015	131
5	Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy European Heart Journal ·Wael Sumaya, Lars Wallentin, Stefan James, Agneta Siegbahn, Katja Gabrysch, Maria Bertilsson, Anders Himmelmänn, Ramzi Ajjan, Robert F. Storey	2018	117
6	The Impact of Smoking on Inhaled Insulin Diabetes Care ·Anders Himmelmänn, Johan Jendle, Á. Callejo Mellén, Astrid H. Petersen, Ulf Dahl, Per Wollmer	2003	89
7	Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up Journal of Hypertension ·Torbjörn Almgren, Lars Wilhelmsen, Ola Samuelsson, Anders Himmelmänn, Annika Rosengren, Ove K. Andersson	2007	87
8	Ambulatory blood pressure 16-26 years after the first urinary tract infection in childhood Journal of Hypertension ·Martin Wennerström, Sverker Hansson, Thomas Hedner, Anders Himmelmänn, Ulf Jodal	2000	85
9	Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization Circulation ·Lars Wallentin, Daniel Lindholm, Agneta Siegbahn, Lisa Wernroth, Richard C. Becker, Christopher P. Cannon, Jan H. Cornel, Anders Himmelmänn, Evangelos Giannitsis, Robert A. Harrington, Claes Held, Steen Husted, Hugo A. Katus, Kenneth W. Mahaffey, Philippe Gabríel Steg, Robert F. Storey, Stefan James	2013	82
10	Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial American Heart Journal ·Hyun‐Jae Kang, Robert M. Clare, (unknown), Claes Held, Anders Himmelmänn, Stefan James, Soo Teik Lim, Anwar Santoso, Cheuk‐Man Yu, Lars Wallentin, Richard C. Becker	2015	80
11	Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial Diabetes Obesity and Metabolism ·Hans Denison, Catarina Nilsson, Lars Löfgren, Anders Himmelmänn, Gunnar Mårtensson, Mikael Knutsson, Ayman Al‐Shurbaji, Hans Törnqvist, Jan W. Eriksson	2013	80
12	The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial European Heart Journal ·Steen Husted, Stefan James, Richard G. Bach, Richard C. Becker, Andrzej Budaj, Manuel Heras, Anders Himmelmänn, Jay Horrow, Hugo A. Katus, Riitta Lassila, João Morais, José Carlos Nicolau, Philippe Gabríel Steg, Robert F. Storey, D. Wojdyla, Lars Wallentin, (unknown)	2014	58
13	Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes JAMA Cardiology ·Daniel Lindholm, Stefan James, Katja Gabrysch, Robert F. Storey, Anders Himmelmänn, Christopher P. Cannon, Kenneth W. Mahaffey, Philippe Gabríel Steg, Claes Held, Agneta Siegbahn, Lars Wallentin	2018	55
14	Association Between Achieved ω-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk JAMA Cardiology ·Steven E. Nissen, A. Michael Lincoff, Kathy Wolski, Christie M. Ballantyne, John J.P. Kastelein, Paul M. Ridker, Kausik K. Ray, Darren K. McGuire, Dariush Mozaffarian, Wolfgang Köenig, Michael H. Davidson, Michelle Garcia, Brian G. Katona, Anders Himmelmänn, Larrye E. Loss, Matthew Poole, Venu Menon, Stephen J. Nicholls	2021	53
15	Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial Journal of the American Heart Association ·Pontus Andell, Stefan James, Christopher P. Cannon, Derek D. Cyr, Anders Himmelmänn, Steen Husted, Mátyás Keltai, Sasha Koul, Anwar Santoso, Philippe Gabríel Steg, Robert F. Storey, Lars Wallentin, David Erlinge, (unknown)	2015	50
16	Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention Heart ·Matthijs A. Velders, Jérémie Abtan, Dominick J. Angiolillo, Diego Ardissino, Robert A. Harrington, Anne S. Hellkamp, Anders Himmelmänn, Steen Husted, Hugo A. Katus, Bernhard Meier, Phillip J. Schulte, Robert F. Storey, Lars Wallentin, Philippe Gabríel Steg, Stefan James	2016	47
17	The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension Journal of Hypertension ·Thomas Hedner, Anders Himmelmänn	1999	46
18	Relation of maternal blood pressure during pregnancy to birth weight and blood pressure in children. The Hypertension in Pregnancy Offspring Study Journal of Internal Medicine ·Anders Himmelmänn, Anna Svensson, L. Hansson	1994	44
19	Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial EuroIntervention ·Grégory Ducrocq, Phillip J. Schulte, Richard C. Becker, Christopher P. Cannon, Robert A. Harrington, Claes Held, Anders Himmelmänn, Riitta Lassila, Robert F. Storey, Emmanuel Sorbets, Lars Wallentin, Philippe Gabríel Steg	2015	42
20	Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial American Heart Journal ·Matthijs A. Velders, Lars Wallentin, Richard C. Becker, Adrianus J. van Boven, Anders Himmelmänn, Steen Husted, Hugo A. Katus, Daniel Lindholm, João Morais, Agneta Siegbahn, Robert F. Storey, Lisa Wernroth, Stefan James	2015	42

About Anders Himmelmänn

Anders Himmelmänn is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism, Surgery and Nephrology, having authored 106 papers that have together received 2.9k indexed citations. Recurring topics across this work include Antiplatelet Therapy and Cardiovascular Diseases (53 papers), Acute Myocardial Infarction Research (21 papers), Lipoproteins and Cardiovascular Health (20 papers), Venous Thromboembolism Diagnosis and Management (16 papers), Blood Pressure and Hypertension Studies (14 papers), Atrial Fibrillation Management and Outcomes (12 papers), Coronary Interventions and Diagnostics (9 papers) and Diabetes Treatment and Management (8 papers). The work is most often cited by research in Internal Medicine (377 citations), Cardiology and Cardiovascular Medicine (1.9k citations), Endocrinology, Diabetes and Metabolism (397 citations), Surgery (743 citations) and Rheumatology (220 citations). Anders Himmelmänn has collaborated with scholars based in Sweden, United States and United Kingdom. Frequent co-authors include Stefan James, Lars Wallentin, Robert F. Storey, Philippe Gabríel Steg, Richard C. Becker, Thomas Hedner, Steen Husted, Hugo A. Katus, Mikael Knutsson and Hans Denison. Their work appears in journals such as American Heart Journal, European Heart Journal, Journal of Hypertension, Journal of the American College of Cardiology and Blood Pressure.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact